Cargando…

贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾

We report an advanced stage Chinese female lung adenocarcinoma patient who was negative for epidermal growth factor receptor (EGFR), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations, also negative for chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000572/
https://www.ncbi.nlm.nih.gov/pubmed/23769349
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.10
_version_ 1783331773273341952
collection PubMed
description We report an advanced stage Chinese female lung adenocarcinoma patient who was negative for epidermal growth factor receptor (EGFR), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations, also negative for chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase (EML4-ALK) gene rearrangement and treated with bevacizumab (15 mg/kg) in combination with 6 cycles of conventional doses of paclitaxel and carboplatin chemotherapy. She was then treated with maintenance bevacizumab for a total of 42 cycles, the total dose of bevacizumab is 44, 730 mg. The progression-free survival was 39 months. Our findings suggest that maintenance bevacizumab for the treatment of non-small cell lung cancer (NSCLC) is safe and its benefit for long-term survival overwhelms its side effects.
format Online
Article
Text
id pubmed-6000572
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60005722018-07-06 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾 Zhongguo Fei Ai Za Zhi 病例报道 We report an advanced stage Chinese female lung adenocarcinoma patient who was negative for epidermal growth factor receptor (EGFR), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations, also negative for chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase (EML4-ALK) gene rearrangement and treated with bevacizumab (15 mg/kg) in combination with 6 cycles of conventional doses of paclitaxel and carboplatin chemotherapy. She was then treated with maintenance bevacizumab for a total of 42 cycles, the total dose of bevacizumab is 44, 730 mg. The progression-free survival was 39 months. Our findings suggest that maintenance bevacizumab for the treatment of non-small cell lung cancer (NSCLC) is safe and its benefit for long-term survival overwhelms its side effects. 中国肺癌杂志编辑部 2013-06-20 /pmc/articles/PMC6000572/ /pubmed/23769349 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.10 Text en 版权所有©《中国肺癌杂志》编辑部2013 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 病例报道
贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾
title 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾
title_full 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾
title_fullStr 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾
title_full_unstemmed 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾
title_short 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾
title_sort 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾
topic 病例报道
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000572/
https://www.ncbi.nlm.nih.gov/pubmed/23769349
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.10
work_keys_str_mv AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù
AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù
AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù
AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù
AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù
AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù
AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù
AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù
AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù
AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù
AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù
AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù